Skip to main content
SpringerLink
Log in

Therapie des SCLC im lokal fortgeschrittenen Stadium

Therapy of small cell lung cancer in the locally advanced stage

  • Leitthema
  • Published:
Der Pneumologe Aims and scope

Zusammenfassung

Etwa 20% der Patienten mit kleinzelligem Lungenkarzinom (SCLC) sind bei Diagnosestellung noch im lokal beschränkten Stadium. Aufgrund der dennoch meist systemischen Erkrankung bzw. raschen Metastasierung ist immer eine systemische Chemotherapie indiziert. Die lokale Kontrolle ist dennoch sowohl für die Symptomatik des Patienten, das Lokalrezidiv und die Gesamtprognose entscheidend. Deshalb sollte früh zusätzlich zur Chemotherapie eine thorakale Strahlentherapie erfolgen. Zumindest bei gutem Ansprechen auf die Chemotherapie und thorakale Strahlentherapie ist eine prophylaktische Ganzhirnbestrahlung zu empfehlen, die das Auftreten von Hirnmetastasen reduziert und auch das Überleben etwas verlängert.

Abstract

About 20% of the patients with small cell lung cancer (SCLC) are still in a limited stage at the time of diagnosis. As nevertheless small cell lung cancer is usually a systemic disease and due to the tendency of this tumour for rapid metastasis systemic chemotherapy is always indicated. Local control is nevertheless important for the symptoms of the patient, the local recurrence and overall prognosis. Therefore thoracic radiotherapy should be applied early during chemotherapy. At least in patients with a good response to chemotherapy and thoracic radiotherapy prophylactic cranial irradiation is recommended, which reduces the occurrence of cerebral metastases and to some extent prolongs survival of these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. American College of Chest Physicians (2003) Lung Cancer Guidelines. Chest 123(1) [Suppl]

  2. Arriagada R, Le Chevalier T, Rivière A et al. (2002) Patterns of failure after prophylactic cranial irradiation in small-cell-lung cancer: analysis of 505 randomized patients. Ann Oncol 13(5): 748–754

    Article  PubMed  CAS  Google Scholar 

  3. Auperin A, Arriagada R, Pignon J-P et al. (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 341: 476–484

    Article  PubMed  CAS  Google Scholar 

  4. De Ruysscher D, Pijls-Johannesma M, Bentzen SM et al. (2006) Time between the first day of chemotherapy and the last day of chest radiation Is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24: 1057–1063

    Article  Google Scholar 

  5. Ettinger DS, Berkey BA, Abrams RA et al. (2005) Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Oncology Group 9609 phase II study. J Clin Oncol 23: 4991–4998

    Article  PubMed  CAS  Google Scholar 

  6. Huber RM (2006) Manual Tumorzentrum München. Tumoren der Lunge und des Mediastinums. W. Zuckschwerdt, Germering bei München. Online über: http://tzm.web.med.uni-muenchen.de

  7. Huncharek M, McGarry R (2004) A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist 9(6): 665–672

    Article  PubMed  Google Scholar 

  8. Jeremic B, Shibamoto Y, Nikolic N et al. (1999) Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 17(7): 2092–2099

    PubMed  CAS  Google Scholar 

  9. Laurie SA, Logan D, Markman BR et al. (2004) Practice guidelines for the role of combination chemotherapy in the initial management of limited stage small-cell lung cancer. Lung Cancer 43: 223–240

    Article  PubMed  Google Scholar 

  10. National Collaborating Centre for Acute Care (2005) Diagnosis and treatment of lung cancer. National Collaborating Centre for Acute Care, London. Online über: http://www.rcseng.ac.uk

  11. Pignon JP, Arriagada R, Ihde DC et al. (1992) Effect of thoracic radiotherapy on mortality in limited small-cell lung cancer: a meta-analysis of 13 randomized trials among 2,140 patients. N Engl J Med 327: 1618–1624

    Article  PubMed  CAS  Google Scholar 

  12. Pijls-Johannesma MCG, De Ruysscher D, Lambin P et al. (2004) Early versus late chest radiotherapy in patients with limited stage small cell lung cancer. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD004700. DOI:10.1002/14651858.CD004700.pub2.

  13. Saito H, Takada Y, Ichinose Y et al. (2006) Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol 24: 5247–5252

    Article  PubMed  CAS  Google Scholar 

  14. Slotman B, Faivre-Finn C, Kramer G et al. (2007) A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993–22993). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S [June 20 Suppl], 2007: 4

  15. Spiro SG, James LE, Rudd RM et al. (2006) Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol 24: 3823–3830

    Article  PubMed  CAS  Google Scholar 

  16. Sundstrøm S, Bremnes RM, Kaasa S et al. (2002) Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years‘ follow-up. J Clin Oncol 20: 4665–4672

    Article  PubMed  Google Scholar 

  17. Turrisi AT, Kim K, Blum R et al. (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposid. N Engl J Med 340: 265–271

    Article  PubMed  CAS  Google Scholar 

  18. Videtic GMM, Stitt LW, Dar AR et al. (2003) Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 21: 1544–1549

    Article  PubMed  Google Scholar 

  19. Warde P, Payne D (1992) Does thoracic irradiation improve survival and local control in limited- stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10: 890−895

    PubMed  CAS  Google Scholar 

  20. Wittekind C, Meyer HJ, Bootz F (2002) TNM-Klassifikation maligner Tumoren. Springer, Berlin Heidelberg New York Tokyo

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung/en hin: Der Autor R.M. Huber und das Klinikum der Universität München nehmen an Studien zum kleinzelligen Lungenkarzinom teil.

Author information

Authors and Affiliations

  1. Pneumologie, Klinikum der Universität München – Innenstadt, Ziemssenstraße 1, 80336, München, Deutschland

    R.M. Huber

  2. Strahlentherapie, Klinikum der Universität München, München, Deutschland

    B. Pöllinger

Authors
  1. R.M. Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Pöllinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R.M. Huber.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huber, R., Pöllinger, B. Therapie des SCLC im lokal fortgeschrittenen Stadium. Pneumologe 4, 337–342 (2007). https://doi.org/10.1007/s10405-007-0165-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-007-0165-9

Schlüsselwörter

Keywords

Search

Navigation